Semper Paratus Acquisition Corporation (NASDAQ:TVGN - Get Free Report)'s stock price fell 2.7% on Wednesday . The stock traded as low as $1.08 and last traded at $1.08. 654,915 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 5,087,844 shares. The stock had previously closed at $1.11.
Analyst Ratings Changes
Separately, D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Semper Paratus Acquisition in a report on Wednesday, June 18th.
Get Our Latest Report on TVGN
Semper Paratus Acquisition Stock Down 0.9%
The company's fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.22.
Insider Buying and Selling at Semper Paratus Acquisition
In other Semper Paratus Acquisition news, CEO Ryan H. Saadi sold 1,438,206 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the completion of the transaction, the chief executive officer owned 116,814,453 shares of the company's stock, valued at $143,681,777.19. This represents a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 73.24% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Semper Paratus Acquisition
Hedge funds have recently bought and sold shares of the company. Barclays PLC increased its position in Semper Paratus Acquisition by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares during the period. Northern Trust Corp grew its stake in Semper Paratus Acquisition by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after purchasing an additional 13,595 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Semper Paratus Acquisition by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the period. XTX Topco Ltd acquired a new stake in shares of Semper Paratus Acquisition in the 4th quarter valued at about $55,000. Finally, Nuveen LLC acquired a new stake in Semper Paratus Acquisition in the first quarter valued at approximately $97,000.
About Semper Paratus Acquisition
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
See Also
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access